VOLUMETRIC MAPPING OF BREAST CANCER BIOMARKERS USING H-S MR SPECTRO IMAGING

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在这个项目中，我们将开发一种基于质子回声平面光谱成像(Pepsi)和并行磁共振成像(SENSE/GRAPPA)的超高速并行磁共振乳房成像技术。我们将评估单次激发的百事可乐超分辨率感觉重建(SURE-SENSE)的可行性，这是一种新的并行MRI形式，特别适用于低分辨率MRSI。这一方法将使用新型16通道乳房射频阵列线圈实施，与传统的射频线圈设计相比，该线圈提供显著更高的灵敏度，并实现更快的并行成像加速。我们在人体乳房的初步结果表明，高质量的2D和3D百事可乐在短时间内是可行的。我们的目标是1)开发用于3T乳腺的超高速并行3D MRSI；以及2)使用3T超高速3D MRSI作为乳腺癌检测和治疗反应评估的工具。如果成功，这项开发的技术将被用作乳腺癌诊断和治疗监测的工具。长期目标是利用MRSI作为接受系统治疗(即化疗、内分泌治疗)的女性治疗失败的早期预测指标，并为高危患者开发改进的筛查方案。在接受新辅助治疗的患者中，准确地及早识别治疗的失败或成功可以节省大量的时间和资源，并将患者风险和暴露于无效药物的潜在副作用降至最低。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In this project we will develop an ultra high-speed parallel MRSI technique for the human breast based on Proton Echo Planar Spectroscopic Imaging (PEPSI) and parallel MRI (SENSE/GRAPPA). We will assess the feasibility of single-shot PEPSI with Superresolution SENSE reconstruction (SURE-SENSE), a novel form of parallel MRI, which is particularly suitable for low resolution MRSI. This methodology will be implemented using a novel 16-channel breast RF array coil that provides significantly higher sensitivity and enables much faster parallel imaging acceleration as compared to conventional RF coil designs. Our preliminary results in the human breast demonstrate the feasibility of high quality 2D and 3D PEPSI in short measurement time. Our aims are to 1) Develop ultra high-speed parallel 3D MRSI for the breast at 3 T; and 2) Use ultra high-speed 3D MRSI at 3 T as a tool for breast cancer detection and treatment response assessment. If successful, the developed technique will be used as a tool for breast cancer diagnosis and treatment monitoring. The long-term goals are to utilize MRSI as an early predictor of treatment failure in women undergoing systemic therapy (i.e. chemotherapy, endocrine therapy) for breast cancer and to develop an improved screening protocol for high-risk patients. In patients undergoing neoadjuvant therapies, accurate early identification of treatment failure or success could save significant time and resources, and minimize patient risk and exposure to potential side effects from medications that are not efficacious.